Evaluation of the EndoPAT as a Tool to Assess Endothelial Function

M. Moerland, A. J. Kales, L. Schrier, M. G. J. van Dongen, D. Bradnock, and J. Burggraaf

Centre for Human Drug Research, Department of Vascular Medicine, Zernikeplein 10, 2333 CL Leiden, The Netherlands

Correspondence should be addressed to M. Moerland, mmoerland@chdr.nl

Received 8 November 2011; Accepted 28 November 2011

Academic Editor: Arnon Blum

Endothelial dysfunction is a potential target for (pharmaceutical) intervention of several systemic pathological conditions. We investigated the feasibility of the EndoPAT to evaluate acute changes in endothelial function with repeated noninvasive measurements and assessed its discriminating power in different populations. Endothelial function was stable over a longer period of time in renally impaired patients (coefficient of variation 13%). Endothelial function in renally impaired and type 2 diabetic patients was not decreased compared to healthy volunteers (2.9 ± 1.4 and 1.8 ± 0.3, resp., versus 1.8 ± 0.5, P > 0.05). The EndoPAT did not detect an effect of robust interventions on endothelial function in healthy volunteers (glucose load: change from baseline 0.08 ± 0.50, 95% confidence interval −0.44 to 0.60; smoking: change from baseline 0.49 ± 0.92, 95% confidence interval −0.47 to 1.46). This suggests that at present the EndoPAT might not be suitable to assess (changes in) endothelial function in early-phase clinical pharmacology studies. Endothelial function as measured by the EndoPAT could be physiologically different from endothelial function as measured by conventional techniques. This should be investigated carefully before the EndoPAT can be considered a useful tool in drug development or clinical practice.

1. Introduction

Endothelial dysfunction is an early predictor of cardiovascular disease [1–3], and might be the causal pathological mechanism of a variety of metabolic diseases, also referred to as the common soil hypothesis [4]. Endothelial function has been shown to be impaired in patients with coronary artery disease, type II diabetes mellitus, hypertension, obesity, renal failure, and hypercholesterolemia [5–9]. It is conceivable that improvement of endothelial function will be an important target in the treatment of these conditions. Therefore, availability of methodology that can be used to reliably assess the effects of (pharmacological) treatments on endothelial function is of critical importance.

Endothelial dysfunction is commonly described as the inability of the artery to sufficiently dilate in response to an appropriate endothelial stimulus. It can be assessed by measurement of the arterial pulse wave at a finger artery or by the measurement of flow-mediated dilation (FMD) of the brachial artery after occlusion of the blood flow. Although the exact mechanisms causing FMD are not entirely known, the main mechanism inducing FMD is thought to be an increase in shear stress, leading to the release of nitric oxide from endothelial cells which causes blood vessel dilation [10]. Currently, FMD is assessed clinically in a noninvasive manner using high-resolution ultrasound of the brachial artery. The technique is widely used and has been shown to be a suitable tool to assess endothelial dysfunction. However, the method has several disadvantages: it is operator dependent [11], and as FMD is measured at one arm only, there are no possibilities to correct for potential measurement-induced changes in the systemic hemodynamics, such as those resulting from alterations in the autonomous nervous system tone. To overcome these problems, the EndoPAT was developed. This device allows non-invasive measurement of vasoreactivity without the disadvantages of conventional ultrasound measurement. The EndoPAT detects plethysmographic pressure changes in the finger tips caused by the arterial pulse and translates this to a peripheral arterial tone (PAT). Endothelium-mediated changes in vascular tone after occlusion of the brachial artery are reflecting a downstream hyperemic response, which is a measure for arterial endothelial function [12]. Measurements on the contralateral arm are
used to control for concurrent nonendothelium-dependent changes in vascular tone. In addition, the EndoPAT provides a measure for arterial stiffness: the augmentation index (AI). In theory, the EndoPAT could be a useful device in clinical research as the test is easy to perform, not operator-dependent, and with comprehensive automatic analysis. In a group of 89 adult patients suffering from chest pain, peripheral arterial tone correlated positively with FMD [12]. In the Framingham study, a significant inverse relation was observed between endothelial function as determined by the EndoPAT (“EndoScore” or reactive hyperemia index, RHI) and multiple cardiovascular risk factors (male sex, body mass index, total/HDL cholesterol, diabetes, smoking, and lipid-lowering treatment) [13]. The EndoScore was reported to be significantly decreased in patients with coronary artery disease, hypertension, hyperlipidemia, diabetes, glucose intolerance, and tobacco users (group sizes of 15 to 70 subjects) [12, 14–18]. Several EndoPAT studies have demonstrated an improvement in endothelial function as a result of lifestyle modification (smoking cessation, and dietary change) [19–22] or prolonged pharmacological intervention [23, 24]. However, there is only limited information on the performance of the EndoPAT for repeated measurements in a relatively short time frame. This information is pertinent as in many clinical (pharmacology) studies repeated measures are performed in populations consisting of 6 to 12 subjects.

Therefore, we performed a series of experiments to investigate the feasibility of the EndoPAT to evaluate acute changes in endothelial function and arterial stiffness with repeated measurements and to assess the discriminating power of the EndoPAT in different populations. First, we investigated the variability of endothelial function and arterial stiffness, as measured by the EndoPAT, in patients with chronic kidney failure on three different days. Endothelial function, as assessed by high-resolution ultrasound, is known to be severely impaired in this patient population, despite intensive treatment (30–60% reduction) [25–28]. In addition, we measured endothelial function and arterial stiffness in patients with diabetes mellitus type 2, another patient population with a strongly reduced endothelial reactivity as determined using conventional techniques (30–35% reduction) [29–31]. Finally, we investigated the capability of the device to detect changes in endothelial function induced by two acute and robust interventions (smoking and glucose administration) in healthy volunteers. Cigarette smoking acutely impairs endothelial function in healthy volunteers by causing oxidative stress and reducing the production of nitric oxide due to the free radicals present in cigarette smoke [2, 32]. Also high blood glucose levels lead to an attenuated endothelial function, as has been demonstrated by plethysmography and high-resolution ultrasound [33, 34].

2. Materials and Methods

The experiments were approved by the Medical Ethics Committee of Leiden University Medical Center (LUMC). Endothelial function and arterial stiffness were assessed in 6 renal patients (creatinine clearance between 30 and 70 mL/min) and 16 patients with diabetes mellitus type 2 (8 using metformin and 8 using metformin plus sulfonylurea). Intervention studies were performed in apparently healthy males and females, not using any medication. In all experiments, subjects were fasted for at least 3 hours before EndoPAT measurements.

2.1. Protocol. Reactive hyperemia index (RHI), which is a measure for endothelial function, and augmentation index (AI), which is a measure for arterial stiffness, were assessed using the EndoPAT 2000 device (Itamar Medical, Israel). Both measures were calculated using a computerised automated algorithm (software version 3.1.2) provided with the device. Measurements were performed according to the manufacturer’s instructions. Briefly, the subjects were in supine position for a minimum of 20 minutes before measurements, in a quiet, temperature-controlled (21–24°C) room with dimmed lights. The subjects were asked to remain as still as possible and silent during the entire measurement period. Each recording consisted of 5 minutes of baseline measurement, 5 minutes of occlusion measurement, and 5 minutes postocclusion measurement (hyperemic period). Occlusion of the brachial artery was performed on the nondominant upper arm. The occlusion pressure was at least 60 mmHg above the systolic blood pressure (minimally 200 mmHg, and maximally 300 mmHg).

2.2. Renal Patient Study Part. Endothelial function and arterial stiffness were investigated in six patients with chronic kidney failure (subject characteristics in Table 1, glomerular filtration rate was estimated by calculation of creatinine clearance using a 24-hour urine collection). All subjects were on maintenance therapy for treatment of hypertension. All measurements were performed in the morning. Per subject, 3 measurements were performed, separated by one to two weeks. Patients were allowed to use medication needed for their medical condition, except for corticosteroids and erythropoietic medication within one month before study participation.

2.3. Diabetic Patient Study Part. Endothelial function and arterial stiffness were investigated in 16 patients with diabetes mellitus type 2 (subject characteristics in Table 2). All subjects were on oral antidiabetics to control glucose metabolism: 8 subjects were using metformin, and 8 subjects were using metformin plus sulfonylurea. Per subject, two EndoPAT measurements were performed: one time during continuation of the antidiabetic therapy and one time after two weeks of therapy discontinuation, with the sequence randomized. All measurements were performed in the evening. Patients were allowed to use medication needed for their medical condition, except for medication known to affect glucose homeostasis (other than biguanides and sulphonylurea), anti-inflammatory drugs, nonselective beta blockers, oral anticoagulants, and systemic glucocorticoids or other immunosuppressive drugs.
| Subject | Gender | Age (years) | BMI (kg/m²) | GFR (mL/min) | BP (mmHg) | HR (bpm) | Maintenance therapy |
|---------|--------|-------------|-------------|--------------|-----------|----------|---------------------|
| 1       | M      | 59          | 24          | 45           | 140/83    | 63       | a, b, c             |
| 2       | M      | 63          | 27          | 47           | 134/82    | 54       | a, c, d, e, f, g    |
| 3       | F      | 57          | 20          | 41           | 138/61    | 67       | a, c, e, h, i       |
| 4       | F      | 46          | 19          | 51           | 120/73    | 58       | b, h                |
| 5       | F      | 59          | 22          | 55           | 150/86    | 64       | a, c                |
| 6       | M      | 65          | 32          | 69           | 140/75    | 75       | a, b, j             |

*statin, calcium channel blocker, ACE inhibitor, thiazide diuretic, platelet aggregation inhibitor, angiotensin II receptor antagonist, intestinal potassium binder, potassium chloride, acetylsalicylic acid, and β1 receptor blocker.

BP: blood pressure (supine).
BMI: body mass index.
GFR: glomerular filtration rate.
HR: heart rate (supine).

### Table 2: Diabetic patients, baseline characteristics.

|                        | Metformin group | Metformin plus sulfonylurea group |
|------------------------|-----------------|----------------------------------|
| Number (male/female)   | 8 (7/1)         | 8 (8/0)                          |
| Age (years)            | 56 ± 8          | 58 ± 6                           |
| BMI (kg/m²)            | 27 ± 3          | 27 ± 4                           |
| Systolic BP (mmHg)     | 137 ± 7         | 142 ± 7                          |
| Diastolic BP (mmHg)    | 83 ± 6          | 79 ± 8                           |
| HR (bpm)               | 70 ± 9          | 74 ± 11                          |
| Glucose (mM)           | 6.3 ± 0.8       | 6.8 ± 3.2                        |
| HbA1c (mM)             | 6.4 ± 0.5       | 6.1 ± 0.6                        |

(Mean ± SD).
BP: blood pressure (supine).
BMI: body mass index.
HR: heart rate (supine).

### 2.4. Oral Glucose Intervention in Healthy Volunteers

Six nonsmoking female subjects (mean age 23 ± 3 years) participated in the oral glucose intervention study part. After the baseline EndoPAT measurement was performed, an oral glucose solution (75 g glucose in 300 mL) was consumed within 4 minutes. At 30 minutes and 90 minutes after the oral glucose consumption, EndoPAT measurements were performed.

### 2.5. Smoking Intervention in Healthy Volunteers

Six male cigarette smoking subjects (mean age 32 ± 10 years) participated in this study part. The number of cigarettes per subject per day ranged between 1 and 20 cigarettes. Subjects refrained from smoking until at least 2 hours before the start of the study. After a baseline measurement was performed, the participants smoked a cigarette (tar 10 mg, nicotine 0.8 mg and carbon monoxide 10 mg) within 4 minutes. At 30 minutes and 90 minutes after smoking, the measurements were repeated.

### 2.6. Data Analysis and Statistics

Unpaired t-tests were used to compare RHI and AI between healthy volunteers and patients and between diabetic patients using metformin only and patients using metformin plus sulfonylurea, while paired t-tests were used to compare RHI and AI between diabetic patients who continued their medication and patients who discontinued their medication. The intervention experiments were carried out in groups of 6 healthy volunteers; a sample size based on the observed intraindividual variability in RHI and the level of impairment of endothelial function determined by conventional techniques (high-resolution ultrasound, plethysmography) in intervention studies as reported in literature. Our experiments were powered such that a group size of 6 would have 80% power to detect a 25% change in baseline RHI using a 2-sided alpha of 5%. Paired t-tests were used to compare the difference in RHI between baseline and the postintervention measurements, which was considered to be statistically significant when $P$ value $< 0.05$.

### 3. Results

To assess the performance of the EndoPAT, we investigated the variability of endothelial function (RHI) and arterial stiffness (AI) in patients with chronic kidney failure on three different days, separated by one to two weeks. Average RHI over three days was 2.9 ± 1.4 (Table 3). For most patients, the RHI values exceeded a value of 2 (range: from 1.7 to 5.5). Official reference values for RHI are not available, but in general RHI values below 2 are categorized as endothelial dysfunction, whereas higher RHI values are considered normal or improved endothelial function (Itamar product information). The average intra-individual variability for
the RHI was 13% (ranging from 1% to 29% for individuals, data not shown). The general estimate for interindividual variability in RHI was 50% (Table 3). Average AI over three days was 26.1 ± 13.9 (Table 4). This is in line with the expectation, as normal arterial stiffness is defined by an AI between −30% and −10%, increased arterial stiffness by an AI between −10% and 10%, and abnormal arterial stiffness by an AI above 10%. The mean intra-individual coefficient of variation was 37% (ranging from 13% to 67%, data not shown). These data indicate that whereas endothelial function is a relatively stable measure over a longer period of time, arterial stiffness as determined by the EndoPAT is rather variable.

Next, we measured endothelial function and arterial stiffness in patients with diabetes mellitus type 2, 8 subjects using metformin and 8 subjects using metformin plus sulfonylurea. Endothelial function and arterial stiffness were determined during continuation of the antidiabetic therapy and after two weeks of therapy discontinuation. Arterial stiffness, as determined by AI, was not different between patients using metformin or metformin plus sulfonylurea or between patients continuing and discontinuing antidiabetic medication (Table 4: 5.9 ± 9.4 versus 9.0 ± 13.0 and 14.3 ± 18.8 versus 16.3 ± 16.0, resp.). However, RHI was significantly higher in patients using a combination of metformin plus sulfonylurea, compared to patients using metformin only (Table 3: 2.5 ± 0.7 versus 1.8 ± 0.3 in patients continuing therapy and 2.7 ± 1.1 versus 1.8 ± 0.4 in patients discontinuing therapy; P = 0.02 and 0.04 resp.). The increasing effect of sulfonylurea treatment on RHI was independent on continuation or discontinuation of the use of antidiabetics.

Finally, we investigated the capability of the EndoPAT to detect changes in endothelial function induced by two acute interventions in healthy volunteers. Neither the oral glucose load nor the smoking intervention resulted in significant effects on endothelial function (Figure 1). For the glucose intervention, the difference in RHI from baseline measurement was 0.08 ± 0.50 (95% CI, confidence interval: from −0.44 to 0.60) for the 30 min assessment and 0.44 ± 0.86 (95% CI: from −0.46 to 1.34) for the 90 min assessment. For the smoking intervention, the difference in RHI from baseline measurement was 0.49 ± 0.92 (95% CI: from −0.47 to 1.46) for the 30 min assessment and 0.39 ± 0.53 (95% CI: from −0.16 to 0.95) for the 90 min assessment.

AI and RHI were compared between the investigated patient groups and the healthy volunteer group. As expected, AI was higher in renal patients compared to healthy subjects (Table 4: 26.1 ± 13.9 in patients versus −6.0 ± 14.2 in healthy volunteers, P = 0.001). AI was also higher in diabetic patients compared to healthy subjects, independent of type of oral antidiabetics (metformin or metformin plus sulfonylurea) or continuation or discontinuation of therapy (Table 4: 5.9 ± 9.4, 9.0 ± 13.0, 14.3 ± 18.8, and 16.3 ± 16.0,

### Table 3: Reactive hyperaemia index.

| Population     | N  | Therapy       | Study period | mean ± SD | min–max | CV   |
|----------------|----|---------------|--------------|-----------|---------|------|
| Renal patients | 6  | N/A           | N/A²         | 2.9 ± 1.4 | 1.7–5.5 | 50%  |
| Diabetic patients | 8 | Metformin    | Cont.        | 1.8 ± 0.3 | 1.5–2.2 | 16%  |
| Diabetic patients | 8 | Metformin    | Discont.     | 1.8 ± 0.4 | 1.1–2.4 | 25%  |
| Diabetic patients | 8 | Metformin + SA | Cont.       | 2.5 ± 0.7** | 1.7–3.7 | 28%  |
| Diabetic patients | 8 | Metformin + SA | Discount.   | 2.7 ± 1.1*** | 1.7–4.9 | 41%  |
| Healthy volunteers | 12 | N/A           | N/A          | 1.8 ± 0.5 | 1.3–2.8 | 29%  |

SA: sulfonylurea; SD: standard deviation; CV: coefficient of variation.
Cont: continuation of therapy; discount: 2 weeks of therapy discontinuation.
*visit 1, 2, and 3 and averaged (see materials and methods).
*P < 0.05 versus healthy volunteers.
**P < 0.05 versus diabetic patients on metformin only.

### Table 4: Augmentation index.

| Population     | N  | Therapy       | Study period | mean ± SD | min–max |
|----------------|----|---------------|--------------|-----------|---------|
| Renal patients | 6  | N/A           | N/A²         | 26.1 ± 13.9* | 13.3–52.0 |
| Diabetic patients | 8 | Metformin    | cont         | 5.9 ± 9.4** | −8.0–22.0 |
| Diabetic patients | 8 | Metformin    | dist         | 14.3 ± 18.9** | 1.0–55.0 |
| Diabetic patients | 8 | Metformin + SA | cont       | 9.0 ± 13.0** | −15.0–24.0 |
| Diabetic patients | 8 | Metformin + SA | dist       | 16.3 ± 16.0** | −6.0–32.0 |
| Healthy volunteers | 12 | N/A           | N/A          | −6.0 ± 14.2 | −25.7–31.7 |

SA: sulfonylurea; SD: standard deviation.
Cont: continuation of therapy; discount: 2 weeks of therapy discontinuation.
*visit 1, 2, and 3 and averaged (see materials and methods).
*P = 0.001 versus healthy volunteers.
**P < 0.05 versus healthy volunteers.
***P < 0.05 versus diabetic patients on metformin only.
Endothelial dysfunction is present in several systemic pathological conditions [5–9], associated with considerable morbidity and mortality. As a consequence, endothelial dysfunction is expected to gain interest as potential target for (pharmaceutical) intervention within the coming years. However, there was no difference in RHI between the renal patients and the healthy volunteers (Table 3: 2.9 ± 1.4 in patients versus 1.8 ± 0.5 in healthy volunteers, \( P = 0.15 \)). Furthermore, RHI values did not differ between diabetic patients using metformin and healthy volunteers (Table 3: 1.8 ± 0.3 in patients continuing therapy and 1.8 ± 0.4 in patients discontinuing therapy versus 1.8 ± 0.5 in healthy volunteers). RHI was significantly higher in diabetic patients using a combination of metformin plus sulfonylurea compared to healthy volunteers (Table 3: 2.5 ± 0.7 in patients continuing therapy and 2.7 ± 1.1 in patients discontinuing therapy; \( P = 0.04 \) and 0.01 resp. versus healthy volunteers).

4. Discussion

Endothelial dysfunction is present in several systemic pathological conditions [5–9], associated with considerable morbidity and mortality. As a consequence, endothelial dysfunction is expected to gain interest as potential target for (pharmaceutical) intervention within the coming years. Currently, endothelial function is assessed mainly by high-resolution ultrasound of the brachial artery. However, this technique has important practical limitations: it is strongly operator-dependent [11], and it offers no correction for autonomous activation of the nervous system, as vascular dilation is only studied in one arm. To overcome these problems, the EndoPAT was developed, allowing noninvasive measurement of endothelial function via assessment of reactive hyperemia. In addition, the EndoPAT provides a measure for arterial stiffness. Although in several studies the EndoPAT appeared to be feasible to demonstrate improvement of endothelial function as a result of lifestyle modification or pharmacological intervention [19–24], the information in literature on the performance of the EndoPAT in intervention trials is limited. Therefore, we performed a series of experiments to investigate the feasibility of the EndoPAT to evaluate acute changes in endothelial function with repeated measurements and to assess the discriminating power of the EndoPAT for endothelial function and arterial stiffness in different populations.

We assessed the variability of endothelial function (by RHI) and arterial stiffness (by AI), as measured by the EndoPAT, in patients with impaired renal function on three different days. Next, we measured endothelial function and arterial stiffness in patients with diabetes mellitus type 2. Finally, we investigated the applicability and feasibility of the EndoPAT to detect changes in endothelial function in healthy volunteers after interventions known to be associated with robust acute changes in endothelial function in an adequately powered experiment.

Generally, augmentation index, calculated from carotid, aortic, or radial artery pressure waves using conventional techniques, is a reliable and reproducible measure to define arterial stiffness [35]. However, the influence of variables such as heart rate and vasomotor tone of the arterial system can affect the variability of the technique [36]. We demonstrated that when using the EndoPAT, the intrindividual variability in AI was substantial over a longer period of time (CV: coefficient of variation, 37%). This indicates that arterial stiffness as determined by the EndoPAT is also not a stable measure, which limits its usefulness to assess the effects of (pharmacological) interventions. Arterial stiffness as measured by the EndoPAT was higher in renally impaired patients with vascular disease compared to healthy subjects. This is in line with reports in literature in patient populations: compared to healthy volunteers, arterial stiffness is increased in a variety of pathological conditions, such as coronary artery disease, metabolic syndrome, and chronic kidney disease [37–39].

Compared with arterial stiffness, RHI proved to be a more stable measure (CV 13%). Surprisingly, endothelial function, as determined by reactive hyperemia index, was not impaired in the renal patient group. Importantly, observed RHI values in the patient population were scattered over a broad range, covering both endothelial dysfunction (RHI < 2) and exceptionally good endothelial function (RHI > 3). Given the fact that all subjects were renally impaired and treated for hypertension, it is very unlikely that 4 out of 6 patients had an (exceptionally) good endothelial function. Obviously, all patients used medication with pertinent effects on endothelial function (Table 1: statins, ACE inhibitors, and calcium channel blockers) [40], but literature data suggest that despite optimal (cardiovascular) therapy, a considerable increased risk for cardiovascular morbidity in this population still exists [41]. Importantly, although most chronic kidney disease patients use antihypertensive medication and other drugs that could affect endothelial function (statins, potassium, and ACE inhibitors), they still exhibit a significantly impaired endothelial function as demonstrated by laser Doppler flowmetry (32% reduction) [25]. Interestingly, Gordon et al. reported that pulse contour analysis obtained by finger plethysmography, which is comparable with the EndoPAT methodology, may not be suitable.
to measure endothelial function in subjects with extensive coronary artery disease, as no effect of administration of strong vasodilators (salbutamol and nitroglycerin) could be observed [42].

We investigated whether the EndoPAT could discriminate in vascular function between healthy volunteers and patients with diabetes mellitus type 2. As expected, arterial stiffness was higher in diabetic patients compared to healthy subjects, irrespective of treatment with oral antidiabetics. However, endothelial function (as measured by the EndoPAT) was not impaired in diabetic patients using metformin compared to healthy volunteers, neither during continuation of treatment nor after two weeks of treatment discontinuation. This is contrasting with literature, which demonstrates that endothelial function, measured using conventional techniques (endothelium-dependent flow-mediated dilatation of the brachial artery, by ultrasound), is substantially impaired in diabetic patients (reduction of endothelial function versus healthy controls or subjects with coronary artery disease without diabetes ranging from 27% to 43%) [29–31]. This discrepancy could not be explained by an effect of treatment with oral antidiabetics, as RHI was assessed both during treatment continuation and after a two-week period of treatment discontinuation.

RHI was significantly increased in patients using a combination of metformin plus sulphonylurea, compared to healthy volunteers and to patients using metformin only. This stimulating effect of sulphonylurea treatment on RHI was still observed after two weeks of treatment discontinuation, implicating a long-lasting effect of sulphonylurea on endothelial function. This is remarkable as the general point of view is that the use of pancreatic β-cell-specific sulphonylurea (i.e., glimepiride, as used by 6 out of 8 diabetic subjects in our study) does not affect endothelial function [43–45]. Possibly, endothelial function as measured by the EndoPAT (RHI) is a physiologically different process than endothelial function as measured by conventional techniques such as high-resolution ultrasound (endothelium-dependent FMD). The exact nature of this difference is currently unknown, and should be investigated in detail before the EndoPAT can be considered a useful tool in drug development or clinical practice.

We evaluated the performance of the EndoPAT to detect the effects of two different acute interventions on RHI in healthy subjects. The literature shows that FMD decreases by 40–65% after smoking one cigarette, which is detected directly after smoking and lasts for 1 hour [2, 32, 46, 47]. Also hyperglycaemia, induced by the administration of a standardised oral glucose load, has been reported to acutely lead to a 25–45% impairment of endothelial function, as assessed by FMD or forearm blood flow plethysmography [33, 34, 48]. However, we were unable to replicate these findings on endothelial function using the EndoPAT, demonstrating that the device is currently not suitable to detect acute changes in endothelial function after different robust interventions. There could be several explanations for our findings. In the automated analysis, the EndoPAT software uses a fixed time frame during the hyperemic response to calculate the RHI. Inspection of the data and manual analysis of the RHI showed that the maximal hyperemic response does not always occur in the same time period after occlusion (data not shown), an observation that is supported by literature. For example, the time course of FMD is strongly influenced by age: comparison of young and older subjects indicates that the time frame to reach maximal vasodilatation after occlusion is significantly prolonged in older subjects [49]. This may be remedied by refinement of the EndoPAT software to allow for interindividual differences in hyperemic time course. Although inter-individual differences in hyperemic time course is a potentially confounding factor when using the automatic analysis, manual analysis of our data did not result in significantly different findings (data not shown). There are some indications that endothelial function is subject to a circadian rhythm, with a lower reactive hyperemic response in the morning [50], but this is not unambiguously supported [51–54]. In fact, the presumed circadian variability is probably more related to changes in physical activity, blood pressure and shear stress, and changes in plasma lipids. Whatever the explanation may be, our experiments were performed within a short fixed time frame of maximally 2 hours, in a fasted condition and in complete rest, thereby reducing the influence of these confounding factors. As a consequence, it is unlikely that circadian variability has influenced our measurement outcomes. Finally, it is possible that previous experiments using ultrasound or plethysmography to assess the acute effect of an intervention on endothelial function are flawed because measurements were performed (in the majority of the cases) in the vasculature of one arm only, and thus relatively uncontrolled for concomitant systemic hemodynamic changes. We consider this a theoretical explanation, but unlikely. We are well aware that the group sizes of our intervention experiments were small and that no formal control groups were included. However, the experiments were sufficiently powered to detect intervention-induced changes in endothelial function at effect sizes that are reported in literature using FMD or forearm blood flow plethysmography.

In conclusion, whereas the reactive hyperemia index (a measure for endothelial function), as determined by the EndoPAT, is rather stable over time, the augmentation index (a measure for arterial stiffness) showed substantial intra-individual variability, limiting its value for evaluation of (pharmacological) interventions. Surprisingly, the EndoPAT did not demonstrate differences in endothelial function between healthy volunteers and renal impaired patients with known vascular disease or diabetic patients. In the latter patient group, an unexplained improving effect of sulphonylurea on reactive hyperemia index was demonstrated by the EndoPAT. This could indicate that endothelial function as measured using the EndoPAT might be physiologically different from endothelial function as measured by conventional techniques. Furthermore, the EndoPAT was not useful to detect the effect of robust interventions on endothelial function while the experiments were adequately powered. Taken together, our findings suggest that the EndoPAT is at present not suitable to assess (changes in) endothelial function while the experiments were adequately powered.
function and arterial stiffness in populations with sizes that are commonly employed in clinical pharmacology studies.

**Abbreviations**

ACE: Angiotensin-converting enzyme  
AI: Augmentation index  
BMI: Body mass index  
BP: Blood pressure  
CI: Confidence interval  
CV: Coefficient of variation  
FMD: Flow-mediated dilation  
GFR: Glomerular filtration rate  
HR: Heart rate  
LUMC: Leiden University Medical Center  
NO: Nitric oxide  
PAT: Peripheral arterial tone  
RHI: Reactive hyperemia index.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**References**

[1] T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, and T. Münnzel, “Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease,” *Circulation*, vol. 104, no. 22, pp. 2673–2678, 2001.

[2] K. Karatzis, C. Papamichael, E. Karatzis et al., “Acute smoking induces endothelial dysfunction in healthy smokers. Is this reversible by red wine’s antioxidant constituents?” *Journal of the American College of Nutrition*, vol. 26, no. 1, pp. 10–15, 2007.

[3] V. Schächinger, M. B. Britten, and A. M. Zeiher, “Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease,” *Circulation*, vol. 101, no. 16, pp. 1899–1906, 2000.

[4] M. P. Stern, “Diabetes and cardiovascular disease: the ‘common soil’ hypothesis,” *Diabetes*, vol. 44, no. 4, pp. 369–374, 1995.

[5] I. Bolad and P. Delafontaine, “Endothelial dysfunction: its role in hypertensive coronary disease,” *Current Opinion in Cardiology*, vol. 20, no. 4, pp. 270–274, 2005.

[6] P. M. Vanhoutte, “Endothelial dysfunction—the first step toward coronary arteriosclerosis,” *Circulation Journal*, vol. 73, no. 4, pp. 595–601, 2009.

[7] M. M. Hartge, T. Unger, and U. Kintscher, “The endothelium and vascular inflammation in diabetes,” *Diabetes and Vascular Disease Research*, vol. 4, no. 2, pp. 84–88, 2007.

[8] M. R. Meyers and N. Gokce, “Endothelial dysfunction in obesity: etiological role in atherosclerosis,” *Current Opinion in Endocrinology, Diabetes and Obesity*, vol. 14, no. 5, pp. 365–369, 2007.

[9] H. Kawano, T. Motoyama, N. Hirai, K. Kugiyma, H. Yasue, and H. Ogawa, “Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress,” *Atherosclerosis*, vol. 161, no. 2, pp. 375–380, 2002.

[10] A. C. Betik, V. B. Luckham, and R. L. Hughson, “Flow-mediated dilation in human brachial artery after different circulatory occlusion conditions,” *American Journal of Physiology*, vol. 286, no. 1, pp. H442–H448, 2004.

[11] R. A. Vogel, M. C. Corretti, and G. D. Plotnick, “A comparison of brachial artery flow-mediated vasodilation using upper and lower arm arterial occlusion in subjects with and without coronary risk factors,” *Clinical Cardiology*, vol. 23, no. 8, pp. 571–575, 2000.

[12] J. T. Kuvin, A. R. Patel, K. A. Sliney et al., “Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude,” *American Heart Journal*, vol. 146, no. 1, pp. 168–174, 2003.

[13] N. M. Hamburg, M. J. Keyes, M. G. Larson et al., “Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham heart study,” *Circulation*, vol. 117, no. 19, pp. 2467–2474, 2008.

[14] J. T. Kuvin, A. Mammen, P. Mooney, A. A. Alsheikh-Ali, and R. H. Karas, “Assessment of peripheral vascular endothelial function in the ambulatory setting,” *Vascular Medicine*, vol. 12, no. 1, pp. 13–16, 2007.

[15] M. J. Haller, J. Stein, J. Shuster et al., “Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes,” *Pediatric Diabetes*, vol. 8, no. 4, pp. 193–198, 2007.

[16] F. H. Mahmud, M. G. Earing, R. A. Lee, A. N. Lteif, D. J. Driscoll, and A. Lerman, “Altered endothelial function in asymptomatic male adolescents with type 1 diabetes,” *Congenital Heart Disease*, vol. 1, no. 3, pp. 98–103, 2006.

[17] F. H. Mahmud, S. Van Uum, N. Kanji, H. Thiesen-Philbrook, and C. L. Clarson, “Impaired endothelial function in adolescents with type 1 diabetes mellitus,” *Journal of Pediatrics*, vol. 152, no. 4, pp. 557–562, 2008.

[18] Y. Shachor-Meyouhas, G. Pillar, and N. Shehadeh, “Uncontrolled type 1 diabetes mellitus and endothelial dysfunction in adolescents,” *Israel Medical Association Journal*, vol. 9, no. 9, pp. 637–640, 2007.

[19] T. A. Barringer, L. Hatcher, and H. C. Sasser, “Potential benefits on impairment of endothelial function after a high-fat meal of 4 weeks of flavonoid supplementation,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 796958, 6 pages, 2011.

[20] N. D. L. Fisher, M. Hughes, M. Gerhard-Herman, and N. K. Hollenberg, “Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans,” *Journal of Hypertension*, vol. 21, no. 12, pp. 2281–2286, 2003.

[21] N. D. L. Fisher and N. K. Hollenberg, “Aging and vascular responses to flavanol-rich cocoa,” *Journal of Hypertension*, vol. 24, no. 8, pp. 1575–1580, 2006.

[22] H. Schroeter, C. Heiss, J. Balzer et al., “(−)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 4, pp. 1024–1029, 2006.

[23] A. Aversa, C. Vitale, M. Volterrani et al., “Chronic administration of Suldenafil improves markers of endothelial function in men with Type 2 diabetes,” *Diabetic Medicine*, vol. 25, no. 1, pp. 37–44, 2008.

[24] T. W. Yeo, D. A. Lamph, R. Gitawati et al., “Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations,” *Journal of Infectious Diseases*, vol. 198, no. 4, pp. 602–608, 2008.

[25] E. Linden, W. Cai, J. C. He et al., “Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition
of endothelial nitric oxide synthase through RAGE activation,” *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 3, pp. 691–698, 2008.

[26] M. Rossi, A. Cupisti, C. Di Maria, F. Galetta, G. Barsotti, and G. Santoro, “Blunted post-ischemic increase of the endothelial skin blood flowmotion component as early sign of endothelial dysfunction in chronic kidney disease patients,” *Microvascular Research*, vol. 75, no. 3, pp. 315–322, 2008.

[27] F. H. Verbeke, M. Agharazii, P. Boutouyrie, B. Pannier, A. P. Guérin, and G. M. London, “Local shear stress and brachial artery functions in end-stage renal disease,” *Journal of the American Society of Nephrology*, vol. 18, no. 2, pp. 621–628, 2007.

[28] A. Kruger, J. Stewart, R. Sahityani et al., “Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk,” *Kidney International*, vol. 70, no. 1, pp. 157–164, 2006.

[29] B. Feng, Y. Chen, Y. Luo, M. Chen, X. Li, and Y. Ni, “Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilatation in patients with type 2 diabetes mellitus,” *Atherosclerosis*, vol. 208, no. 1, pp. 264–269, 2010.

[30] T. Kaborab, A. Kaya, A. Temizihan, F. Koç, S. Yavuz, and S. Çam, “The influence of homocysteine levels on endothelial function and their relation with microvascular complications in T2DM patients without macrovascular disease,” *Acta Diabetologica*, vol. 44, no. 2, pp. 69–75, 2007.

[31] G. Reyes-Soffer, S. Holleran, M. R. Di Tullio et al., “Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus,” *Metabolism*, vol. 59, no. 9, pp. 1365–1371, 2010.

[32] J. A. Ambrose and R. S. Barua, “The pathophysiology of cigarette smoking and cardiovascular disease: an update,” *Journal of the American College of Cardiology*, vol. 43, no. 10, pp. 1731–1737, 2004.

[33] L. M. Title, P. M. Cummings, K. Giddens, and B. A. Nasar, “Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E,” *Journal of the American College of Cardiology*, vol. 36, no. 7, pp. 2185–2191, 2000.

[34] S. B. Williams, A. B. Goldfine, F. K. Timimi et al., “Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo,” *Circulation*, vol. 97, no. 17, pp. 1695–1701, 1998.

[35] W. W. Nichols and B. M. Singh, “Augmentation index as a measure of peripheral vascular disease state,” *Current Opinion in Cardiology*, vol. 17, no. 5, pp. 543–551, 2002.

[36] X. Wang, J. C. Keith, A. D. Struthers, and G. Z. Feuerstein, “Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk,” *Cardiovascular Therapeutics*, vol. 26, no. 3, pp. 214–223, 2008.

[37] T. Weber, J. Auer, M. F. O’Rourke et al., “Arterial stiffness, wave reflections, and the risk of coronary artery disease,” *Circulation*, vol. 109, no. 2, pp. 184–189, 2004.

[38] G. P. Vyssoulis, P. G. Pietri, E. A. Karpanou et al., “Differential impact of metabolic syndrome on arterial stiffness and wave reflections: focus on distinct definitions,” *International Journal of Cardiology*, vol. 138, no. 2, pp. 119–125, 2010.

[39] S. S. Deloach, L. I. Appel, J. Chen et al., “Aortic pulse pressure is associated with carotid IMT in chronic kidney disease: report from chronic renal insufficiency cohort,” *American Journal of Hypertension*, vol. 22, no. 12, pp. 1235–1241, 2009.

[40] L. Lind, S. O. Granstam, and J. Millgård, “Endothelium-dependent vasodilation in hypertension: a review,” *Blood Pressure*, vol. 9, no. 1, pp. 4–15, 2000.

[41] A. Levine, O. Djurdjev, B. Barrett et al., “Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter,” *American Journal of Kidney Diseases*, vol. 38, no. 6, pp. 1398–1407, 2001.

[42] S. E. Gordon, N. Cartwright, and M. J. D. Griffiths, “Investigation of endothelial function by pulse contour analysis: a protocol for drug administration and timing of pulse contour assessment,” *British Journal of Clinical Pharmacology*, vol. 68, no. 4, pp. 630–633, 2009.

[43] E. J. Abbinck, P. Pickkers, A. Jansen Van Rosendaal et al., “Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients,” *Diabetic Medicine*, vol. 19, no. 2, pp. 136–143, 2002.

[44] K. Papathanassiou, K. K. Naka, N. Kazakos et al., “Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes,” *Atherosclerosis*, vol. 205, no. 1, pp. 221–226, 2009.

[45] P. Spallarossa, M. Schiavo, P. Rossettini et al., “Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia,” *Diabetes Care*, vol. 24, no. 4, pp. 738–742, 2001.

[46] G. Siassos, D. Tousoulis, C. Vlachopoulos et al., “The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance,” *American Journal of Hypertension*, vol. 22, no. 6, pp. 586–592, 2009.

[47] A. M. Esen, I. Barutcu, M. Acar et al., “Effect of smoking on endothelial function and wall thickness of brachial artery,” *Circulation Journal*, vol. 68, no. 12, pp. 1123–1126, 2004.

[48] W. Zhu, C. Zhong, Y. Yu, and K. Li, “Acute effects of hyperglycaemia with and without exercise on endothelial function in healthy young men,” *European Journal of Applied Physiology*, vol. 99, no. 6, pp. 585–591, 2007.

[49] M. A. Black, N. T. Cable, D. H. J. Thijsen, and D. J. Green, “Importance of measuring the time course of flow-mediated dilatation in humans,” *Hypertension*, vol. 51, no. 2, pp. 203–210, 2008.

[50] M. Montagnana, G. L. Salvagno, and G. Lippi, “Circadian variation within hemostasis: an underrecognized link between biology and disease?” *Seminars in Thrombosis and Hemostasis*, vol. 35, no. 1, pp. 23–33, 2009.

[51] H. Kawano, T. Motoyama, H. Yasue et al., “Endothelial function fluctuates with diurnal variation in the frequency of ischemic episodes in patients with variant angina,” *Journal of the American College of Cardiology*, vol. 40, no. 2, pp. 266–270, 2002.

[52] J. A. Shaw, J. P. F. Chin-Dusting, B. A. Kingwell, and A. M. Dart, “Diurnal variation in endothelium-dependent vasodilatation is not apparent in coronary artery disease,” *Circulation*, vol. 103, no. 6, pp. 806–812, 2001.

[53] M. E. Otto, A. Svatíkova, R. B. De Mattos Barretto et al., “Early morning attenuation of endothelial function in healthy humans,” *Circulation*, vol. 109, no. 21, pp. 2507–2510, 2004.

[54] M. J. Järvisalo, L. Jartti, J. Marniemi et al., “Determinants of short-term variation in arterial flow-mediated dilatation in healthy young men,” *Clinical Science*, vol. 110, no. 4, pp. 475–482, 2006.